發(fā)布時間：2018-03-08 08:38

  本文選題：上市醫(yī)藥企業(yè)　切入點：知識產(chǎn)權(quán)管理　出處：《遼寧大學》2017年碩士論文　論文類型：學位論文

【摘要】：知識經(jīng)濟日益發(fā)展,知識產(chǎn)權(quán)已經(jīng)成為經(jīng)濟全球化大背景下企業(yè)競爭的關(guān)鍵所在。各大企業(yè)為了更好地融入到全球化中,提高企業(yè)的核心競爭力以應(yīng)對激烈的市場競爭,提高企業(yè)自身的知識產(chǎn)權(quán)管理水平已成為當務(wù)之急。本文基于我國醫(yī)藥企業(yè)知識產(chǎn)權(quán)的具體特征,結(jié)合相關(guān)理論研究,一方面,有針對性地把握知識產(chǎn)權(quán)、知識產(chǎn)權(quán)管理以及醫(yī)藥企業(yè)這三者之間的關(guān)系;另一方面,從知識產(chǎn)權(quán)管理全過程的視角出發(fā),建立了針對我國醫(yī)藥企業(yè)的知識產(chǎn)權(quán)管理績效評價指標體系;在此基礎(chǔ)上,采用模糊綜合評價法構(gòu)建模型。更進一步選取我國上市醫(yī)藥樣本企業(yè)進行實證評價。本文旨在對我國醫(yī)藥企業(yè)知識產(chǎn)權(quán)管理績效的評價提供科學可操作的方法,并對完善我國醫(yī)藥企業(yè)知識產(chǎn)權(quán)管理工作提出合理的意見和建議,以期促進我國醫(yī)藥企業(yè)的可持續(xù)發(fā)展。(1)本文在對知識產(chǎn)權(quán)、企業(yè)知識產(chǎn)權(quán)管理、績效評價相關(guān)理論及醫(yī)藥企業(yè)知識產(chǎn)權(quán)管理特征等進行分析的基礎(chǔ)上,結(jié)合已有研究和我國醫(yī)藥企業(yè)知識產(chǎn)權(quán)管理具體實踐,認為對醫(yī)藥企業(yè)的知識產(chǎn)權(quán)管理存在顯著影響的有五個方面,分別為:知識產(chǎn)權(quán)管理平臺建設(shè)、知識產(chǎn)權(quán)研發(fā)與運用、知識產(chǎn)權(quán)保護、知識產(chǎn)權(quán)經(jīng)營及知識產(chǎn)權(quán)戰(zhàn)略。在此基礎(chǔ)上,構(gòu)建了針對我國醫(yī)藥企業(yè)的知識產(chǎn)權(quán)管理績效評價指標體系。進一步根據(jù)研究需要,本文選取了模糊綜合評價法作為具體的評價方法,也在此基礎(chǔ)上建立了醫(yī)藥企業(yè)知識產(chǎn)權(quán)管理績效的評價模型。(2)選取醫(yī)藥行業(yè)中具有較高競爭力的健康元藥業(yè)集團股份有限公司,運用本文構(gòu)建的醫(yī)藥企業(yè)知識產(chǎn)權(quán)管理績效評價模型進行實證評價研究。通過研究得出,即便是對于在醫(yī)藥行業(yè)百強榜上名列前茅的上市企業(yè),其全過程的知識產(chǎn)權(quán)管理績效也只是處于一般水平,只在知識產(chǎn)權(quán)管理的部分過程處于“較好”等級,而總體水平卻差強人意。這說明我國醫(yī)藥企業(yè)對知識產(chǎn)權(quán)的管理有待加強,需要進一步改善醫(yī)藥企業(yè)的知識產(chǎn)權(quán)管理工作。
[Abstract]:With the development of knowledge economy, intellectual property has become the key of enterprise competition under the background of economic globalization. In order to better integrate into the globalization, improve the core competitiveness of enterprises to cope with the fierce market competition. It has become an urgent task to improve the intellectual property management level of enterprises. Based on the specific characteristics of intellectual property rights of pharmaceutical enterprises in China, this paper combines relevant theoretical research, on the one hand, to grasp intellectual property rights in a targeted manner. The relationship between intellectual property management and pharmaceutical enterprises; on the other hand, from the perspective of the whole process of intellectual property management, the performance evaluation index system of intellectual property management for pharmaceutical enterprises in China is established. The fuzzy comprehensive evaluation method is used to construct the model. Furthermore, the listed pharmaceutical sample enterprises in China are selected for empirical evaluation. The purpose of this paper is to provide a scientific and operable method for evaluating the intellectual property management performance of Chinese pharmaceutical enterprises. In order to promote the sustainable development of pharmaceutical enterprises in China, the author puts forward some reasonable opinions and suggestions to improve the intellectual property management of pharmaceutical enterprises in China. Based on the analysis of the relevant theories of performance evaluation and the characteristics of intellectual property management of pharmaceutical enterprises, combined with the existing research and the specific practice of intellectual property management of pharmaceutical enterprises in China, It is concluded that there are five aspects that have significant influence on the intellectual property management of pharmaceutical enterprises, namely, the construction of intellectual property management platform, the development and application of intellectual property rights, and the protection of intellectual property rights. The intellectual property management and intellectual property strategy. On this basis, the performance evaluation index system of intellectual property management for pharmaceutical enterprises in China is constructed. In this paper, the fuzzy comprehensive evaluation method is selected as the concrete evaluation method. On this basis, the evaluation model of intellectual property management performance of pharmaceutical enterprises is established. Using the intellectual property management performance evaluation model of pharmaceutical enterprises constructed in this paper to carry out empirical evaluation research. Through the research, it is concluded that, even for the top 100 listed companies in the pharmaceutical industry, The whole process of intellectual property management performance is only in the general level, only in part of the process of intellectual property management in the "better" level, However, the overall level is not satisfactory, which indicates that the management of intellectual property in Chinese pharmaceutical enterprises needs to be strengthened, and the management of intellectual property rights in pharmaceutical enterprises should be further improved.
【學位授予單位】：遼寧大學
【學位級別】：碩士
【學位授予年份】：2017
【分類號】：F426.72;F273.1

【參考文獻】

相關(guān)期刊論文 前10條

1 賀巧玲;;中國醫(yī)藥產(chǎn)業(yè)結(jié)構(gòu)與知識產(chǎn)權(quán)保護[J];科技與法律;2016年02期

2 陳俊霖;宋硯秋;王云亭;張笑語;王志鋒;;知識產(chǎn)權(quán)管理績效評價:一種基于專家意見遴選的模糊綜合評判模型[J];中國科技資源導刊;2014年06期

3 顧曉燕;;自主創(chuàng)新模式對高技術(shù)產(chǎn)業(yè)知識產(chǎn)權(quán)創(chuàng)造影響的實證研究[J];軟科學;2014年01期

4 李潭;陳偉;;基于灰類白化模型的知識產(chǎn)權(quán)管理績效評價[J];統(tǒng)計與決策;2013年19期

5 劉海波;李黎明;;面向“創(chuàng)新2020”的知識產(chǎn)權(quán)戰(zhàn)略布局的分析與建議[J];中國科學院院刊;2013年04期

6 郭亞星;;論醫(yī)藥企業(yè)知識產(chǎn)權(quán)戰(zhàn)略[J];中國西部科技;2013年06期

7 趙嘉茜;宋偉;葉胡;;高技術(shù)產(chǎn)業(yè)知識產(chǎn)權(quán)運營績效研究[J];中國高�？萍�;2013年Z1期

8 顧曉燕;;中國高技術(shù)產(chǎn)業(yè)知識產(chǎn)權(quán)創(chuàng)造影響因素的實證檢驗[J];經(jīng)濟學家;2012年11期

9 馮楚建;唐恒;付麗穎;;醫(yī)藥企業(yè)知識產(chǎn)權(quán)管理與績效分析——基于國家高新技術(shù)開發(fā)區(qū)的調(diào)查[J];科技進步與對策;2012年03期

10 陳偉;康鑫;馮志軍;田世海;;基于群組決策特征根法的高技術(shù)企業(yè)知識產(chǎn)權(quán)開發(fā)評價指標識別[J];科技進步與對策;2011年11期

相關(guān)碩士學位論文 前3條

1 朱春華;基于提升企業(yè)競爭優(yōu)勢的知識產(chǎn)權(quán)管理研究[D];江蘇大學;2010年

2 張夏莉;中國高新技術(shù)企業(yè)跨國經(jīng)營中知識產(chǎn)權(quán)管理體系構(gòu)建[D];哈爾濱工程大學;2009年

3 張序晶;企業(yè)利用知識產(chǎn)權(quán)獲得競爭優(yōu)勢研究[D];東北大學;2005年

，

本文編號：1583163